Clinical trial Recruiting at 2 sites Interventional Ages 10 to 46

Comparing a new software for eye refraction with traditional methods

Official title: Randomized Controlled Study on Subjective Refraction by Software Eye Test Technology Versus Retinoscopy

Run by Beijing Airdoc Technology Co., Ltd. · NCT06059521 · Data updated 2026-11-12

This study is testing a new eye refraction software called Mobilerone to see if it gives accurate results for adults and older children with nearsightedness and astigmatism compared to traditional methods.

Quick facts

Study typeInterventional
Ages10 Years to 46 Years
SexAll
Enrollment120 (estimated)
SponsorBeijing Airdoc Technology Co., Ltd.
Industry-sponsored
Locations3 sites (Beijing, Beijing Municipality and 2 other locations)
StatusRecruiting
StartedJuly 15, 2023
Main results expectedDecember 30, 2025
Study endsDecember 30, 2030
Registry record updatedSeptember 28, 2023
Trial IDNCT06059521 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults and older children with myopia and astigmatism who meet specific visual and health criteria.

Probably not a fit

Patients with hyperopia, presbyopia, or significant eye conditions such as keratoconus will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the accuracy and safety of a novel software refraction device called Mobilerone for adults and older children with myopia and astigmatism. Participants will undergo refraction testing using the Mobilerone software, which provides a subjective guide on screen, and the results will be compared to traditional retinoscopy methods. The aim is to determine if the software can provide reliable refractive measurements for those with ametropia. The study will include individuals with specific visual acuity and eye health criteria.

Why it matters

Potential benefit: If successful, this study could lead to a more accurate and user-friendly method for assessing refractive errors in patients with myopia and astigmatism.

How similar studies have gone: While the approach of using software for refraction is innovative, similar studies have shown promise in improving refractive assessment accuracy.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* • subject with ametropia on each eye ≤-12.00D

  * subject with best corrected visual acuity ≥ 20/25, no amblyopia
  * subject with normal transparency of eyes
  * subject with a healthy fundus that does not reveal major abnormalities that may affect vision due to the fluctuate situations
  * subject able to cooperate with the screen and the operator
  * subject without heavy drug treatment that may affect vision as synthetic antimalarials, corticosteroids
  * non-diabetic subject
  * non nystagmus subject
  * non-strabismus subject
  * subject who has not had eye surgery less than 1 year old

Exclusion Criteria:

* • subject with a topography showing an anomaly (keratoconus type or other)

  * subject with hyperopia or presbyopia
  * subject with mild myopia ≥ -1.00D
  * subject who cannot speak with the operator including those staff of local optometrists or ophthalmologists

Where it's running

  • Jenny QIU
    Beijing, Beijing Municipality, China
    Recruiting
  • Qiu Jenny
    Beijing, Haidian District, China
    Recruiting
  • Airdoc MPC Opthalmology Clinics
    Beijing, Beijing Municipality, China
    Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.